Printer Friendly

NEORX APPOINTS JACK L. BOWMAN TO BOARD OF DIRECTORS; NUMBER OF BOARD MEMBERS INCREASES TO TEN

 SEATTLE, Jan. 11 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced that it has elected Jack L. Bowman, recently retired company group chairman at Johnson & Johnson Company (J&J), to its board of directors, expanding the number of board seats to 10.
 "We are extremely pleased to have someone with Jack Bowman's experience and savvy join our board at this exciting point in NeoRx's development," said Paul G. Abrams, M.D., J.D., NeoRx's president and chief executive officer. "As our OncoTrac(R) product moves closer to commercialization, we are now focusing our efforts on two substantial therapeutic products, one for cancer and another for cardiovascular disease. Jack Bowman's experience will be particularly helpful in guiding the company's efforts in forming strategic alliances that will speed the development and maximize the potential of these products."
 Mr. Bowman joined J&J in 1987. In his most recent position, he was responsible for a group of pharmaceutical and diagnostic companies generating annual sales in excess of $1 billion. Prior to his association with J&J, he was executive vice president of American Cyanamid Corporation and president of its Lederle Laboratories Division. His career also includes 21 years at Ciba-Geigy where he held various positions including executive vice president responsible for sales and marketing.
 "I am pleased to have joined NeoRx's board and look forward to helping the company grow," said Mr. Bowman. "I have been impressed with how NeoRx has focused and executed their strategy during the last few years. The products under development have the potential to provide major improvements in the treatment of critical illnesses."
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human diseases. To date, the company's activities have been primarily devoted to developing monoclonal antibody-based pharmaceutical products for the diagnosis and treatment of certain types of cancer. NeoRx's lead product under development is a lung cancer diagnostic imaging product, for which the company has filed with the FDA a Product License Application.
 The company's cancer therapy products under development employ its proprietary pretargeting technology, which is designed to deliver high doses of radiation to tumor cells while minimizing toxicity to normal tissue as compared with conventional chemotherapy and radiation treatment. The company is also developing a product designed to reduce restenosis following coronary balloon angioplasty.
 -0- 1/11/94
 /CONTACT: Robert M. Littauer, senior vice president, chief financial officer of NeoRx Corporation, 206-286-2519, or Kathryn C. Comba of Noonan/Russo Communications, 212-696-4455, ext. 206/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MCT SU: PER

TM -- NY006 -- 0837 01/11/94 08:31 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1994
Words:427
Previous Article:JACOBS AWARDED ENGINEERING PROJECT FROM MOBIL OIL CORP.
Next Article:CYPRUS AMAX NAMES F.J. KANE AS V.P. INVESTOR RELATIONS, TREASURER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters